BU-CMD Chemical Library Consortium: Fostering Collaborations between Chemists and Biologists for Translational Discovery

项目总结和摘要 BU-CMD化学图书馆联盟： 促进化学家和生物学家之间的合作，以促进转化发现 小分子是理解生物系统的强大工具，并且构成了大多数生物系统的基础 人类疾病的治疗。将生物活性小分子成功转化为安全有效的 治疗需要化学家和生物学家的共同参与。波士顿大学研究中心 分子发现（BU-CMD）是一个实验室，连接化学家谁使分子与生物学家， 我希望在各种疾病中测试它们。BU-CMD作为一个协作纽带， 连接，播种新的发现，并提供进一步发展所需的关键化学支持 现有的铅。该计划的目标是在多个CTSA中利用现有的BU-CMD资源 中心，建立可扩展的分子分布基础设施，用于播种和促进协作 化学家和转化科学家之间的研究项目。该项目的首要目标是 推进具有挑战性的生物疾病领域的治疗研究。BU-CMD拥有长期的经验 在策划和公开分发一个小分子筛选收集的多样化，结构复杂， 化学型，通过一个独特的，本土的生物筛选协会称为化学图书馆 财团（“CLC”）。CLC在促进新发现和培养有意义的 合作跟进这些发现，以实现转化药物发现。该提案描述了 通过建立一个基于CTSA的开放获取的CLC与CTSA的正式连接 以波士顿大学为中心的复合共享网络。U 01计划将在2015年 来自六个CTSA中心（波士顿大学、纽约大学、北方大学）的合成有机化学家 卡罗莱纳、查佩尔山、加州大学洛杉矶、芝加哥大学和圣母大学 并将在CLC网络内分发。CLC网络将作为这笔赠款的一部分扩大 包括范德比尔特大学和马萨诸塞州医科大学的新翻译科学家 学校中心。最后，将在BU-CMD和NCATS之间建立正式联系， 翻译科学家的资源和技术开发在这里。该联盟旨在连接 CTSA中心的科学资源，并在这些中心的翻译科学家之间建立新的合作 中心，并改善现有的基础设施，以发现和发展小分子疗法， 疾病

PROJECT SUMMARY AND ABSTRACT BU-CMD Chemical Library Consortium: Fostering Collaborations between Chemists and Biologists for Translational Discovery Small molecules are powerful tools for understanding biological systems, and form the foundation for most therapies of human disease. The successful translation of a bioactive small molecule into a safe, effective therapeutic requires the collective involvement of both chemists and biologists. The Boston University Center for Molecular Discovery (BU-CMD) is a laboratory that connects chemists who make molecules with biologists who wish to test them in various diseases. The BU-CMD serves as a collaborative nexus that bridges these connections, seeding new discoveries and providing the critical chemistry support required to further develop existing leads. The objective of this program is to leverage existing BU-CMD resources across multiple CTSA hubs, establishing an expandable molecule distribution infrastructure for seeding and fostering collaborative research projects between chemists and translational scientists. The overarching goal of the project is to advance curative research for challenging biological disease areas. The BU-CMD has longstanding experience in curating and openly distributing a small molecule screening collection of diverse, structurally complex chemotypes, through a unique, homegrown consortium of biological screeners called the Chemical Library Consortium ("CLC"). The CLC has been unique in its ability to enable new discoveries and foster meaningful collaborative follow-up on these discoveries toward translational drug discovery. This proposal describes the formal connection of the CLC with the CTSA through the establishment of an open access, CTSA-based compound sharing network centered at Boston University. The proposed U01 program will curate molecules from synthetic organic chemists at six CTSA hubs (Boston University, New York University, University of North Carolina, Chapel Hill, University of California Los Angeles, The University of Chicago, and University of Notre Dame) and will distribute them within the CLC network. The CLC network will be expanded as part of this grant to include new translational scientists at the Vanderbilt University and University of Massachusetts Medical School hubs. Lastly, a formal connection will be forged between the BU-CMD and NCATS in order to connect translational scientists to resources and technologies developed herein. This consortium aims to connect scientific resources across CTSA hubs, and seed new collaborations between translational scientists at these hubs, and improve upon existing infrastructure for the discovery and progression of small molecule therapies for diseases.